MDII

The Medical Delta Imaging Institute. Image-based technology for improved diagnosis and treatment: cardiovascular & neurodegenerative disease.

What we do

The Medical Delta Imaging Institute (MDII) focuses on developing innovative imaging-based technologies for diagnostics, prognostics and the assessment of treatment of patients suffering from cardiovascular and neurovascular diseases.
MDII will validate how effectively these techniques improve public health, and will translate them into commercially viable solutions for clinical practice.

In terms of directions for research, our focus is on developing preventative measures that can be implemented in people’s homes, and treatments that are targeted and precise. In short, we want people to be able to take control of their own health so that they live healthier, more active and longer lives.

Mission

The Medical Delta Imaging Institute (MDII) will create focus and mass in cardio- and neurovascular medical device development. The Mission of MDII is to reduce morbidity and mortality associated with cardiovascular and neurodegenerative diseases.

MDII Vision

It is MDII’s vision that imaging technology can help decreasing healthcare costs associated with diseases by: developing early and specific diagnostic tools that allow for a shift from treatment to prevention; developing prognostic tools that allow for personalized prognosis and a tailor-made therapeutic strategy; developing tools to assess the treatment efficacy in an early phase, allowing for faster installment of an optimal (personalized) therapy.

To reduce morbidity and mortality associated with cardiovascular and neurodegenerative diseases, the following advances are required:

  • improved (early and differential) diagnosis
  • improved (personalized) prognosis
  • improved (personalized) treatment planning and monitoring

Synergistic improvements in medical image acquisition technology and subsequent analysis are essential to achieve these advances.

MDII will implement these technologies in the context of large epidemiological and clinical studies to derive novel imaging biomarkers of cardio- and neurovascular disease. Moreover, it will valorize validated techniques through industries in medical imaging and pharmaceuticals.

Projects:

Heart in 4D project

Cardiovascular diseases are the main cause of death in industrialised countries. The aim of the Heart in 4D project was both improve the diagnosis and therapy planning of cardiovascular disease. To achieve this, software was developed within the project to determine the volume, composition of athero … Lees meer

Technical leader:
Prof. dr. Wiro Niessen

Wiro Niessen is full professor in Biomedical Image Analysis at Erasmus MC, Rotterdam where he leads the Biomedical Imaging Group Rotterdam (www.bigr.nl) and at Delft University of Technology.

His research interest is in the development, validation and implementation of quantitative imaging biomarkers in clinical practice and biomedical research. Focus areas are neurodegenerative disease, atherosclerosis, and oncology. His research group is active in biological image analysis and improved image guidance in minimally invasive interventions. He has published over 200 journal articles in these areas.

He is chief scientific officer of Quantib BV, which develops quantitative medical image analysis techniques to support diagnosis and therapy of neurological and cardiovascular diseases.

He is fellow and executive director of the Medical Image Computing and Computer Assisted Interventions Society, and director of the Biomedical Image Analysis Platform of the European Institute of Biomedical Imaging Research.

In 2015 he received the Simon Stevin Master award, the largest prize in the Netherlands in the field of Applied Sciences.

Medical leader:
Prof. dr. Mark van Buchem

Mark van Buchem is professor of neuroradiology at the Leiden University Medical Center and head of the Neuroimaging Research Group. In research, his technological interests are MRI techniques, in particular quantitative and functional methodologies, and the diseases of the brain his research focuses on are aging and dementia, lupus erythematosus, and migraine.